CTLA4 and neoplasm: Moreover, one of the first studies of the addition of CTLA-4 antibody failed to increase the clinical response to a Granulocyte/Macrophage/Colony Stimulating/Factor (GM-CSF) gene-transduced tumor cell vaccine (GVAX) while augmenting the tumor destruction by patient T cells [9].